Video

Dr. Donnellan on Developing Combinations in AML

Author(s):

William B. Donnellan, MD

In Partnership With:

William B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, discusses combinations in light of newly FDA-approved agents in acute myeloid leukemia (AML).

William B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, discusses combinations in light of newly FDA-approved agents in acute myeloid leukemia (AML).

In 2017, there were many FDA approvals in the world of AML. Now, physicians are determining optimal combinations for their patients. In patients with secondary AML who also have a FLT3 mutation, the focus of research will be in determining whether there is an added benefit in combining CPX-351 (Vyxeos) with a FLT3 inhibitor like midostaurin (Rydapt), or some of the second-generation FLT3 inhibitors with the IDH2 inhibitor, enasidenib (Idhifa).

Combinations with developing drugs are also being investigated. The big story at the 2017 ASH Annual Meeting was venetoclax. In newly diagnosed AML, the agent showed high response rates when used in combination with a hypomethylating agent. Rates of response are almost 3 times what would be expected with a hypomethylating agent alone.

There's also a big phase III study that’s launching that will compare azacitidine either in combination with venetoclax or placebo. That could potentially change the treatment paradigm for elderly patients who are not fit for induction.

Related Videos
Erminia Massarelli, MD, PhD, MS
Karen L. Reckamp, MD, MS
Jacob Sands, MD, oncology medical director, International Patient Center, Dana-Farber Cancer Institute; assistant professor, Harvard Medical School
Fred R. Hirsch, MD, PhD, executive director, Center for Thoracic Oncology, The Tisch Cancer Institute at Mount Sinai; Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology), Icahn School of Medicine at Mount Sinai
Lori Wirth, MD
Tanios Bekaii-Saab, MD, FACP
Moritz Fürstenau, MD
Jun Gong, MD
Thierry Facon, MD
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Related Content
Vivek Subbiah, MD, chief, early-phase drug development, Sarah Cannon Research Institute
July 11th 2024

Dual Targeting of the mTOR Pathway May Enhance Antitumor Activity in Solid Malignancies

Ian Flinn, MD, PhD; Nicole Lamanna, MD; Jennifer R. Brown, MD, PhD; Constantine Tam, MD, MBBS
February 16th 2023

FDA Approval Insights: Zanubrutinib in CLL and SLL

Minoo Battiwalla, MD, MS, of Sarah Cannon Research Institute
June 19th 2024

Battiwalla Talks Bispecific Antibodies, BTK Inhibitors, and Emerging Therapies in Hematologic Malignancies

Melissa L. Johnson, MD
December 15th 2022

FDA Approval Insights: Tremelimumab Plus Durvalumab and Chemotherapy in NSCLC

Erika Hamilton, MD, of Sarah Cannon Research Institute
June 5th 2024

Second-Line T-DXd Data Remain Strong in HER2+ Metastatic Breast Cancer

David R. Spigel, MD, of Sarah Cannon Research Institute
June 2nd 2024

Consolidation Durvalumab to Become New SOC for LS-SCLC After Chemoradiation